{"nctId":"NCT00520676","briefTitle":"Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer","startDateStruct":{"date":"2007-10"},"conditions":["Non-Small Cell Lung Cancer"],"count":260,"armGroups":[{"label":"pemetrexed plus carboplatin","type":"EXPERIMENTAL","interventionNames":["Drug: pemetrexed","Drug: carboplatin"]},{"label":"docetaxel plus carboplatin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: docetaxel","Drug: carboplatin"]}],"interventions":[{"name":"pemetrexed","otherNames":["LY231514","Alimta"]},{"name":"docetaxel","otherNames":[]},{"name":"carboplatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient with locally advanced or metastatic (Stage IIIB/IV) NCSLC with no prior chemotherapy for advanced disease or molecular target treatment\n* Easter Cooperative Oncology Group (ECOG) performance status 0 to 2\n* Estimated life expectancy of at least 8 weeks\n\nExclusion Criteria:\n\n* Known or suspected brain metastases\n* Concurrent administration of any other tumor therapy\n* Serious concomitant disorders\n* Pregnancy or breast feeding\n* Inability or unwillingness to take folic acid or vitamin B12 supplementation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Survival Without Grade 3 or 4 Toxicity","description":"Defined as the time from date of randomization to first date of a Grade 3 or 4 treatment-emergent adverse event (TEAE; as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events \\[CTCAE\\], version 3.0) or death due to any cause. Grade 3 TEAE: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated. Grade 4 TEAE: Life-threatening consequences; urgent intervention indicated.\n\nParticipants who were alive without experiencing Grade 3 or 4 toxicity were censored at the date of last contact.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is the duration from enrollment to death. For participants who are alive, OS is censored at the last contact.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.9","spread":null},{"groupId":"OG001","value":"14.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS)","description":"Defined as the time from date of first dose to the first observation of disease progression (PD), or death due to any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":null},{"groupId":"OG001","value":"6.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Tumor Response (Response Rate)","description":"Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes not meeting above criteria. Response rate (%)=Number of participants with CR+PR/Number of participants analyzed \\*100. Disease Control rate=Number of participants with SD+PR+CR/Number of participants analyzed \\*100.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.0","spread":null},{"groupId":"OG001","value":"23.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.5","spread":null},{"groupId":"OG001","value":"64.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.0","spread":null},{"groupId":"OG001","value":"23.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.6","spread":null},{"groupId":"OG001","value":"41.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":null},{"groupId":"OG001","value":"17.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":null},{"groupId":"OG001","value":"18.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Duration of Response","description":"The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. CR=disappearance of all target lesions; PR=at least a 30% decrease in sum of longest diameter of target lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"5.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Survival Without Clinically Important Grade 3 or 4 Toxicity","description":"Survival without Grade 3 or 4 toxicity is the time from date of randomization to the first date of the following clinically important Grade 3 or 4 TEAEs graded by the Common Terminology Criteria for Adverse Events \\[CTCAE\\], version 3.0: neutropenia (lasting \\>5 days), febrile neutropenia, documented infections related to neutropenia, anemia, thrombocytopenia, fatigue, nausea, vomiting, diarrhea, stomatitis, and neurosensory events; or death due to any cause. Participants who were alive without experiencing Grade 3 or 4 toxicity were censored for this analysis at the date of last contact.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Survival Without Grade 4 Toxicity","description":"Survival without Grade 4 toxicity is the time from the date of randomization to the first date of a Grade 4 TEAE or death due to any cause. Participants who are alive without experiencing Grade 4 toxicity will be censored for this analysis at the date of last contact.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs)","description":"Summaries of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":28,"n":106},"commonTop":["Neutropenia","Leukopenia","Nausea","Decreased appetite","Alopecia"]}}}